The paper points toward innovative treatments targeting neuroendocrine dysfunction, including CRH antagonists, IRS p53 agonists, and hormone receptor modulators, potentially offering more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback